Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shot shows promise for major weight loss

NCT ID NCT06388187

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 300 adults took part, receiving either CagriSema or a dummy shot once a week for around 1½ years. The main goals were to see how much weight they lost and how many achieved at least a 5% weight reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

300 people

The number who actually took part.

Started

Jun 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * Age above or equal to 18 years at the time of signing informed consent 1. Body Mass index (BMI) greater than or equal to (≥) 30.0 kilogram per meter square (kg/m\^2) or 2. BMI ≥27.0 kg/m2 with the presence of at least one obesity related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening * History of type 1 or type 2 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Addenbrooke's Hospital_Cambridge

    Cambridge, CB2 0QQ, United Kingdom

  • AmBeNet GmbH

    Leipzig, 04107, Germany

  • Aurora FDRC Inc.

    Costa Mesa, California, 92627, United States

  • Capital Clin Res Ctr,LLC

    Olympia, Washington, 98502, United States

  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec

    Saint-Herblain, 44800, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil

    Toulouse, 31059, France

  • Clinical Trial Res Assoc,Inc

    Plantation, Florida, 33324, United States

  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann

    Witten, 58455, Germany

  • Hospices Civils de Lyon-Hopital Lyon Sud

    Pierre-Bénite, 69310, France

  • Hospices Civils de Lyon-Hopital Lyon Sud-1

    Pierre-Bénite, 69310, France

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

    Münster, 48145, Germany

  • Joint Clinical Research Facility - Swansea

    Swansea, SA2 8PP, United Kingdom

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Southmead Hospital

    Bristol, BS10 5NB, United Kingdom

  • Staploe Medical Centre

    Soham, CB7 5JD, United Kingdom

  • The Health Centre

    Bradford-on-Avon, BA15 1DQ, United Kingdom

  • University Hospital Coventry - WISDEM Centre

    Coventry, CV2 2DX, United Kingdom

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Wendisch - Dahl Hamburg - DZHW

    Hamburg, 22607, Germany

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.